8 results about "Lysophosphatidylcholine" patented technology

The present application relates to the technical field of feed additive, and discloses a lactation-promoting functional feed for lactating sows containing high-efficiency plant lactogenic factors, which is made of the following raw materials: sodium-based montmorillonite, fenugreek extract, motherwort extract, ion intensity regulator, lysophosphatidylcholine, tributyl citrate and high-purity silicon dioxide, and is prepared through the following steps: mixing and drying sodium-based montmorillonite with the ion intensity regulator to prepare a regulation carrier; adding fenugreek and motherwort extract and mixing them by strong shearing to form an active core; atomizing and spraying a mixture of lysophosphatidylcholine and tributyl citrate on the surface of the core to form a functional layer; and finally adding high-purity silicon dioxide and mixing uniformly to obtain the feed. Through the construction of the structure with ion-pretreated montmorillonite as the core and the functional layer as the shell, the present application realizes the protection, sustained release and efficient absorption of the active ingredients, and improves the bioavailability.

The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for evaluating the prognosis of patients with hypertrophic cardiomyopathy and application thereof. The application determines that one or more of 3-hydroxyrilotene, asparagine-lysine, cyclohexylamine, arachidonic acid, aconitic acid, propionyl carnitine, ceramide, tryptophan, 3-hydroxysebacic acid, traumatic acid, phosphatidylcholine, alanine-proline, lysophosphatidylcholine, taurine and S-garlicin cysteine are related to the prognosis of hypertrophic cardiomyopathy, can evaluate the prognosis of patients with hypertrophic cardiomyopathy after undergoing muscle resection of interventricular septum, and shows accurate judgment on all-cause death or rehospitalization, cardiovascular events and postoperative new-onset arrhythmia. Finally, all the prognostic biomarkers are reproduced in an independent cohort, which is helpful for postoperative risk evaluation of patients with hypertrophic cardiomyopathy, has high specificity and high sensitivity.

This invention provides an application and method of lysophosphatidylcholine (LPC) in promoting early development of reconstructed embryos, belonging to the field of embryo engineering technology. The invention first prepares reconstructed embryos, then adds lysophosphatidylcholine to the culture system for culturing. Lysophosphatidylcholine effectively promotes early development of the reconstructed embryos; at an optimal concentration of 5 μM, the blastocyst development rate increases to 24.56%, providing a novel and operable biochemical intervention target to solve the problem of low reconstructed embryo culture efficiency. This invention not only fills the gap in our understanding of the mechanism of action of LPC in this field, but also achieves controllability and reproducibility of the technical solution through precise definition of the optimal concentration. It provides key parameters for establishing standardized culture procedures and provides a more solid foundation for downstream applications such as developmental biology research and disease model construction that rely on high-quality reconstructed embryos, significantly accelerating the process of related scientific discovery and application development.

The invention relates to an emulsifying agent characterized in that it comprises 5% to 30% by weight of lysophosphatidylcholine (LPC)-enriched phospholipids in a suitable vehicle. The invention also relates to the use of this emulsifying agent in the preparation of topical compositions, particularly cosmetics, and to said compositions themselves.

The present invention relates to a lipid complex for the nasal delivery of nucleic acid molecules comprising ionized lipids, structural lipids, cholesterol, and lysoPC as active ingredients. The lipid complex of the present invention can be usefully utilized for the local and intensive delivery of therapeutic nucleic acid molecules specifically to nasal epithelial cells by efficiently being compatible with the microenvironment unique to nasal tissue, easily penetrating the mucus layer barrier, and effectively escaping endosomes. Furthermore, the lipid complex of the present invention can be applied as a combination administration platform that induces a synergistic therapeutic effect by two pharmacological components by loading additional drugs into internal compartments of the lipid complex, as well as improving dispersibility by loading the target nucleic acid molecule externally.

This invention relates to the field of animal feed technology and discloses a compound nutritional feed suitable for the growth and development of Ili horses in high-altitude and cold regions. The feed comprises 88-92 parts roughage and 8-12 parts solid-dispersed microspheres. The solid-dispersed microspheres are made of hydrogenated palm oil, calcium propionate, anhydrous citric acid, and lysophosphatidylcholine, and have a lipid crystalline network structure. In an aqueous environment, the lysophosphatidylcholine within the microspheres establishes hydration channels, promoting water penetration and triggering an in-situ acid-base metathesis reaction between calcium propionate and anhydrous citric acid. The resulting liquid free propionic acid causes a sharp drop in the local melting point of the microspheres, leading to the disintegration of the macroscopic structure. This invention can simultaneously release free propionic acid and hydrogenated palm oil, providing energy through gluconeogenesis and intestinal enzymatic hydrolysis, respectively, achieving a dual-effect synergistic energy supply from carbohydrates and lipids. This meets the energy metabolism needs of Ili horses in high-altitude and cold environments and exhibits good long-term storage stability.

The method for improving the extreme acid stress tolerance of Lactobacillus kefiranofaciens disclosed by the scheme belongs to the technical field of microorganisms and comprises the following steps: step one, strain activation: adding glycerophosphocholine into a modified MRS culture medium, then inoculating Lactobacillus kefiranofaciens for activation culture to obtain an activated bacterial solution; step two, stress adaptation culture: inoculating the activated bacterial solution obtained in step one into a stress adaptation culture medium, performing stress domestication by gradually reducing the pH, and adding lysophosphatidylcholine during the domestication process, and then performing culture to obtain a domesticated bacterial solution; and step three, fermentation system strengthening: inoculating the domesticated bacterial solution obtained in step two into a target fermentation system, and supplementing glycerophosphocholine or its hydrochloride into the fermentation system for fermentation. The method can significantly improve the survival ability and metabolic stability of Lactobacillus kefiranofaciens in an extreme acid environment.

The application provides a lysophosphatidylcholine (LPC) kit with anti-coccidiosis effect, and discloses a diagnosis marker for Eimeria tenella infected chicken, which is characteristic phospholipid and sphingolipid molecules, and specifically phosphatidylcholine (PC), lysophosphatidylcholine (LPC) and sphingomyelin (SM). Meanwhile, the application provides a medicine composition for improving the survival rate of chicks infected with Eimeria tenella, which is characterized by containing effective amounts of 18:2 LPA, 18:1 LPC, 22:0 LPC, 16:0 18:1 PC, 16:0 18:2 PC and d18:1 16:0 SM. The application screens characteristic phospholipid and sphingolipid molecules in the cecum tissue of chicken infected with Eimeria tenella for the first time, and verifies the curative effect of phosphatidylcholine (PC), lysophosphatidylcholine (LPC) and sphingomyelin (SM) on acute infection of chicks with Eimeria tenella, which has great market development prospect.